These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1404 related items for PubMed ID: 18505912

  • 1. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [Abstract] [Full Text] [Related]

  • 6. Annual zoledronic acid for osteoporosis.
    BMJ Group.
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [Abstract] [Full Text] [Related]

  • 7. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 8. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 9. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF.
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [Abstract] [Full Text] [Related]

  • 10. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 11. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 12. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S, Vanderschueren D, Venken K, Milisen K, Delforge M, Haentjens P.
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [Abstract] [Full Text] [Related]

  • 13. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 14. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP.
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [Abstract] [Full Text] [Related]

  • 15. A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations.
    Brown JP, Adachi JD, Kendler DL, Rigal R, Deutsch G, Leclerc JM.
    Contemp Clin Trials; 2011 Sep; 32(5):741-6. PubMed ID: 21628001
    [Abstract] [Full Text] [Related]

  • 16. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
    Hadji P, Gamerdinger D, Spieler W, Kann PH, Loeffler H, Articus K, Möricke R, Ziller V.
    Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
    [Abstract] [Full Text] [Related]

  • 17. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE.
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [Abstract] [Full Text] [Related]

  • 18. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM.
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [Abstract] [Full Text] [Related]

  • 20. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A.
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.